nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A biobank perspective on use of tissue samples donated by trial participants
|
Speirs, Valerie |
|
|
23 |
5 |
p. e205 |
artikel |
2 |
Accelerated approval requirements for lurbinectedin
|
Benjamin, David J |
|
|
23 |
5 |
p. e206 |
artikel |
3 |
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial
|
Hussain, Syed A |
|
|
23 |
5 |
p. 650-658 |
artikel |
4 |
Biden's proposed investment in cancer research sparks concerns
|
Das, Manjulika |
|
|
23 |
5 |
p. 576 |
artikel |
5 |
Bridging the equity gap in patient education: the biliary tract cancer BABEL project
|
Casolino, Raffaella |
|
|
23 |
5 |
p. 568-570 |
artikel |
6 |
Cancer care crisis in the Palestinian territories
|
Das, Manjulika |
|
|
23 |
5 |
p. 575 |
artikel |
7 |
Carcinogenicity of cobalt, antimony compounds, and weapons-grade tungsten alloy
|
Karagas, Margaret R |
|
|
23 |
5 |
p. 577-578 |
artikel |
8 |
Correction to Lancet Oncol 2021; 22: 1250–64
|
|
|
|
23 |
5 |
p. e207 |
artikel |
9 |
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
|
Nitz, Ulrike |
|
|
23 |
5 |
p. 625-635 |
artikel |
10 |
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial
|
Heindel, Walter |
|
|
23 |
5 |
p. 601-611 |
artikel |
11 |
Equity in national cancer control plans in the region of the Americas
|
Loggetto, Patrícia |
|
|
23 |
5 |
p. e209-e217 |
artikel |
12 |
Failure to tackle workforce shortages threatens cancer survival progress in England
|
Wilkinson, Emma |
|
|
23 |
5 |
p. e208 |
artikel |
13 |
FDA decisions on new oncological drugs
|
Li, Guanqiao |
|
|
23 |
5 |
p. 583-585 |
artikel |
14 |
FDA decisions on new oncological drugs
|
Benjamin, David J |
|
|
23 |
5 |
p. 585-586 |
artikel |
15 |
G-CSF-induced carotid inflammation
|
Singh, Harshabad |
|
|
23 |
5 |
p. e235 |
artikel |
16 |
Has Pakistan failed to roll back HPV?
|
Awan, Usman Ayub |
|
|
23 |
5 |
p. e204 |
artikel |
17 |
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial
|
Zapatero, Almudena |
|
|
23 |
5 |
p. 671-681 |
artikel |
18 |
IAEA reviews plan to release treated water from Fukushima
|
Das, Manjulika |
|
|
23 |
5 |
p. 574 |
artikel |
19 |
Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group
|
Morana, Giovanni |
|
|
23 |
5 |
p. e218-e228 |
artikel |
20 |
Is tailored systemic therapy in renal cell carcinoma realistic?
|
Kondo, Tsunenori |
|
|
23 |
5 |
p. 555-557 |
artikel |
21 |
Long-term versus short-term androgen deprivation combined with EBRT for unfavourable prostate cancer
|
Crook, Juanita |
|
|
23 |
5 |
p. 558-560 |
artikel |
22 |
Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer
|
Quesada, Stanislas |
|
|
23 |
5 |
p. 557-558 |
artikel |
23 |
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
|
Vano, Yann-Alexandre |
|
|
23 |
5 |
p. 612-624 |
artikel |
24 |
Oncologists in social media—what are the limits?
|
The Lancet Oncology, |
|
|
23 |
5 |
p. 553 |
artikel |
25 |
Ongoing crisis in Ukraine continues to affect cancer care
|
Burki, Talha Khan |
|
|
23 |
5 |
p. 573 |
artikel |
26 |
Patient-reported outcomes: what really matters to patients?
|
Hasanov, Elshad |
|
|
23 |
5 |
p. e198 |
artikel |
27 |
Patient-reported outcomes: what really matters to patients? – Authors' reply
|
Cella, David |
|
|
23 |
5 |
p. e199 |
artikel |
28 |
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
|
Diaz Jr, Luis A |
|
|
23 |
5 |
p. 659-670 |
artikel |
29 |
Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study
|
Thiruchelvam, Paul T R |
|
|
23 |
5 |
p. 682-690 |
artikel |
30 |
Proud about PRADA: radiotherapy before deep inferior epigastric perforator flap reconstruction
|
Kaidar-Person, Orit |
|
|
23 |
5 |
p. 560-562 |
artikel |
31 |
Re-engaging EU citizens with national screening programmes and cancer diagnosis post-pandemic
|
Baird, Anne-Marie |
|
|
23 |
5 |
p. 566-567 |
artikel |
32 |
Resilience and perseverance under siege: providing cancer care during the invasion of Ukraine
|
Kizub, Darya |
|
|
23 |
5 |
p. 579-583 |
artikel |
33 |
Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study
|
McPhail, Sean |
|
|
23 |
5 |
p. 587-600 |
artikel |
34 |
Screening for breast cancer brain metastases
|
Knisely, Jonathan |
|
|
23 |
5 |
p. e200 |
artikel |
35 |
Screening for breast cancer brain metastases – Authors' reply
|
Yan, Min |
|
|
23 |
5 |
p. e201 |
artikel |
36 |
Should tomosynthesis replace mammography for breast cancer screening?
|
Houssami, Nehmat |
|
|
23 |
5 |
p. 554-555 |
artikel |
37 |
Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431
|
Orgel, Etan |
|
|
23 |
5 |
p. 570-572 |
artikel |
38 |
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial
|
Saji, Shigehira |
|
|
23 |
5 |
p. 636-649 |
artikel |
39 |
The DRUG Access Protocol: access inequality and European harmonisation
|
Polak, Tobias B |
|
|
23 |
5 |
p. e202 |
artikel |
40 |
The DRUG Access Protocol: access inequality and European harmonisation – Authors' reply
|
van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh |
|
|
23 |
5 |
p. e203 |
artikel |
41 |
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint
|
Richardson, Nicholas C |
|
|
23 |
5 |
p. 563-566 |
artikel |
42 |
Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials
|
Fiero, Mallorie H |
|
|
23 |
5 |
p. e229-e234 |
artikel |
43 |
War-torn Afghanistan and cancer care: where to focus?
|
Awan, Usman Ayub |
|
|
23 |
5 |
p. 562-563 |
artikel |